Transdermal fentanyl in cachectic cancer patients

Pain

Volumn 144, Issue 1-2, 2009, Pages 218-222

  Heiskanen, Tarja ^a   Mätzke, Sorjo ^b   Haakana, Soile ^a   Gergov, Merja ^c   Vuori, Erkki ^c   Kalso, Eija ^a,c  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b JORVI HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Absorption; Cachexia; Cancer pain; Opioid; Transdermal fentanyl

Indexed keywords

FENTANYL; OXYCODONE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; CACHEXIA; CANCER CHEMOTHERAPY; CANCER PAIN; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; FEMALE; HEADACHE; HUMAN; MALE; NAUSEA; PRIORITY JOURNAL; SKIN IRRITATION; SKIN PERMEABILITY; SKIN TEMPERATURE; SKINFOLD; VISUAL ANALOG SCALE; VOMITING;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; ANALGESICS, OPIOID; BODY MASS INDEX; CACHEXIA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; FENTANYL; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PAIN; PAIN MEASUREMENT; TIME FACTORS; YOUNG ADULT;

EID: 67349108027     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2009.04.012     Document Type: Article

References (25)

1. Ahmedzai S., and Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manage 13 (1997) 254-261
2. Allan L., Hays H., Jensen N.H., de Waroux B.L., Bolt M., Donald R., and Kalso E. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 322 (2001) 1154-1158
3. Ashburn M.A., Ogden L.L., Zhang J., Love G., and Basta S.V. The pharmacokinetics of transdermal fentanyl delivered with and without controlled heat. J Pain 4 (2003) 291-297
4. Baracos V.E. Cancer-associated cachexia and underlying biological mechanisms. Annu Rev Nutr 26 (2006) 435-461
5. Dellemijn P.L., van Duijn H., and Vanneste J.A. Prolonged treatment with transdermal fentanyl in neuropathic pain. J Pain Symptom Manage 16 (1998) 220-229
6. Donner B., Zenz M., Tryba M., and Strumpf M. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain 64 (1996) 527-534
7. Eun H.C. Evaluation of skin blood flow by laser Doppler flowmetry. Clin Dermatol 13 (1995) 337-347
8. Freynhagen R., von Giesen H.J., Busche P., Sabatowski R., Konrad C., and Grond S. Switching from reservoir to matrix systems for the transdermal delivery of fentanyl: a prospective, multicenter pilot study in outpatients with chronic pain. J Pain Symptom Manage 30 (2005) 289-297
9. Gourlay G.K. Treatment of cancer pain with transdermal fentanyl. Lancet Oncol 2 (2001) 165-172
10. Grond S., Radbruch L., and Lehmann K.A. Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl. Clin Pharmacokinet 38 (2000) 59-89
11. Grond S., Zech D., Lehmann K.A., Radbruch L., Breitenbach H., and Hertel D. Transdermal fentanyl in the long-term treatment of cancer pain: a prospective study of 50 patients with advanced cancer of the gastrointestinal tract or the head and neck region. Pain 69 (1997) 191-198
12. Hadgraft J., and Lane M.E. Skin permeation: the years of enlightenment. Int J Pharm 305 (2005) 2-12
13. Hediger C., Rost B., and Itin P. Cutaneous manifestations in anorexia nervosa. Schweiz Med Wochenschr 130 (2000) 565-575
14. Heiskanen T., and Kalso E. Controlled-release oxycodone and morphine in cancer related pain. Pain 73 (1997) 37-45
15. Koltzenburg M., Pokorny R., Gasser U.E., and Richarz U. Differential sensitivity of three experimental pain models in detecting the analgesic effects of transdermal fentanyl and buprenorphine. Pain 126 (2006) 165-174
16. Menten J., Desmedt M., Lossignol D., and Mullie A. Longitudinal follow-up of TTS-fentanyl use in patients with cancer-related pain: results of a compassionate-use study with special focus on elderly patients. Curr Med Res Opin 18 (2002) 488-498
17. Morley J.E., Thomas D.R., and Wilson M.M. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 83 (2006) 735-743
18. Muijsers R.B., and Wagstaff A.J. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs 61 (2001) 2289-2307
19. Portenoy R.K., Southam M.A., Gupta S.K., Lapin J., Layman M., Inturrisi C.E., and Foley K.M. Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics. Anesthesiology 78 (1993) 36-43
20. Rose P.G., Macfee M.S., and Boswell M.V. Fentanyl transdermal system overdose secondary to cutaneous hyperthermia. Anesth Analg 77 (1993) 390-391
21. Roy S.D., and Flynn G.L. Transdermal delivery of narcotic analgesics: pH, anatomical, and subject influences on cutaneous permeability of fentanyl and sufentanil. Pharm Res 7 (1990) 842-847
22. Sandler A.N., Baxter A.D., Katz J., Samson B., Friedlander M., Norman P., Koren G., Roger S., Hull K., and Klein J. A double-blind, placebo-controlled trial of transdermal fentanyl after abdominal hysterectomy. Analgesic, respiratory, and pharmacokinetic effects. Anesthesiology 81 (1994) 1169-1180
23. Solassol I., Bressolle F., Caumette L., Garcia F., Poujol S., Culine S., and Pinguet F. Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-h transdermal applications in cancer pain patients. Ther Drug Monit 27 (2005) 491-498
24. Thompson J.P., Bower S., Liddle A.M., and Rowbotham D.J. Perioperative pharmacokinetics of transdermal fentanyl in elderly and young adult patients. Br J Anaesth 81 (1998) 152-154
25. Varvel J.R., Shafer S.L., Hwang S.S., Coen P.A., and Stanski D.R. Absorption characteristics of transdermally administered fentanyl. Anesthesiology 70 (1989) 928-934